Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: The practical evidence of antidiabetic monotherapy study

Diabetes and Metabolism Journal

Volumn 35, Issue 1, 2011, Pages 26-33

  Yoon, Kun Ho ^a   Shin, Jeong Ah ^a   Kwon, Hyuk Sang ^a   Lee, Seung Hwan ^a   Min, Kyung Wan ^b   Ahn, Yu Bae ^a   Yoo, Soon Jib ^a   Ahn, Kyu Jeung ^c   Park, Sung Woo ^d   Lee, Kwan Woo ^e   Sung, Yeon Ah ^f   Park, Tae Sun ^g   Kim, Min Seon ^h   Kim, Yong Ki ⁱ   Nam, Moon Suk ^j   Kim, Hye Soon ^k   Park, Ie Byung ^l   Park, Jong Suk ^m   Woo, Jeong Taek ⁿ   Son, Ho Young ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Ajou University School of Medicine   (South Korea)

^f Ewha Womans University School of Medicine   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ Pusan National University School of Medicine   (South Korea)

^j Inha University School of Medicine   (South Korea)

^k Keimyung University School of Medicine   (South Korea)

^l Gachon University   (South Korea)

^m Yonsei University College of Medicine   (South Korea)

ⁿ Kyung Hee University Hospital   (South Korea)

more..

Author keywords

Diabetes mellitus; Glimepiride; Metformin; Rosiglitazone; Type 2

Indexed keywords

EID: 84856623197     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2011.35.1.26     Document Type: Article

References (21)

1. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 2001;50:590-3.
2. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8.
3. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40.
4. World Economics Forum. Global risks 2009: a global risk network report. Geneva: World Economics Forum; 2009.
5. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007;30 Suppl 1:S4-41.
6. Riddle MC. Oral pharmacologic management of type 2 diabetes. Am Fam Physician 1999;60:2613-20.
7. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 2004;116 Suppl 5A:23S-9S.
8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
9. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med 2005;22: 980-5.
10. Task Force Team of Korean Diabetes Association. Treatment guideline for diabetes. 1st ed. Seoul: Korean Diabetes Association; 2007. p48-58.
11. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-26.
12. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483-90.
13. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
14. Tan M, Johns D, Gonzalez Galvez G, Antunez O, Fabian G, Flores-Lozano F, Zuniga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004;26:680-93.
15. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999; 58 Suppl 1:31-9.
16. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004;18:367-76.
17. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004;26:177-90.
18. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.
19. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
20. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18 Suppl 2:S23-9.
21. Sohn TS, Lee JI, Kim IJ, Min KW, Son HS. The effect of rosiglitazone and metformin therapy, as an initial therapy, in patients with type 2 diabetes mellitus. Korean Diabetes J 2008;32:445-52.